Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FXR 314

Next Previous
X
Search
Drug Profile

FXR 314

Alternative Names: FXR-314; MET-642

Latest Information Update: 16 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metacrine
  • Developer Metacrine; Organovo Holdings
  • Class Amides; Anti-inflammatories; Benzene derivatives; Cyclohexanes; Cyclopropanes; Hepatoprotectants; Pyrazoles; Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Liver disorders

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis
  • Phase I Hepatic fibrosis; Inflammatory bowel diseases
  • Preclinical Gastroenteritis

Most Recent Events

  • 09 May 2024 Organovo Holdings plans a phase II trial in Inflammatory bowel disease
  • 15 Apr 2024 Efficacy and adverse event data from a phase-II trial in Non-alcoholic steatohepatitis released by Organovo Holdings
  • 08 Apr 2024 FXR 314 is available for licensing as of 08 Apr 2024. https://organovo.com/pipeline/

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top